OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Seon‐Mi Lee, Sanghoon Lee, Hyun‐Woong Cho, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 974-974
Open Access | Times Cited: 17
Seon‐Mi Lee, Sanghoon Lee, Hyun‐Woong Cho, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 974-974
Open Access | Times Cited: 17
Showing 17 citing articles:
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1501-1508
Open Access | Times Cited: 21
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1501-1508
Open Access | Times Cited: 21
Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors
Anna Pawłowska, Anna K. Rekowska, Weronika Kuryło, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10859-10859
Open Access | Times Cited: 25
Anna Pawłowska, Anna K. Rekowska, Weronika Kuryło, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10859-10859
Open Access | Times Cited: 25
The emerging and challenging role of PD-L1 in patients with gynecological cancers: An updating review with clinico-pathological considerations
Angela Santoro, Giuseppe Angelico, Frediano Inzani, et al.
Gynecologic Oncology (2024) Vol. 184, pp. 57-66
Open Access | Times Cited: 14
Angela Santoro, Giuseppe Angelico, Frediano Inzani, et al.
Gynecologic Oncology (2024) Vol. 184, pp. 57-66
Open Access | Times Cited: 14
A comprehensive review on the potential of coumarin and related derivatives as multi-target therapeutic agents in the management of gynecological cancers
Gökçe Şeker Karatoprak, Berrak Altınsoy, Engin Celep, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 8
Gökçe Şeker Karatoprak, Berrak Altınsoy, Engin Celep, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 8
Immune checkpoint inhibitors in gynecological cancers: a narrative review on the practice-changing trials
Cecilia Nasso, Silvia Puglisi, Sara Elena Rebuzzi, et al.
Immunotherapy (2025), pp. 1-10
Closed Access
Cecilia Nasso, Silvia Puglisi, Sara Elena Rebuzzi, et al.
Immunotherapy (2025), pp. 1-10
Closed Access
Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors
Lin Zhou, Yicong Wan, Lin Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116733-116733
Open Access | Times Cited: 3
Lin Zhou, Yicong Wan, Lin Zhang, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116733-116733
Open Access | Times Cited: 3
VISTA: A promising target for overcoming immune evasion in gynecologic cancers
Sicong Liu, Feng Ji, Yue Ding, et al.
International Immunopharmacology (2024) Vol. 138, pp. 112655-112655
Closed Access | Times Cited: 3
Sicong Liu, Feng Ji, Yue Ding, et al.
International Immunopharmacology (2024) Vol. 138, pp. 112655-112655
Closed Access | Times Cited: 3
Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis
Ya‐Fang Chen, Xiaomei Liu, Ying Hu, et al.
Medicine (2024) Vol. 103, Iss. 18, pp. e38019-e38019
Open Access | Times Cited: 2
Ya‐Fang Chen, Xiaomei Liu, Ying Hu, et al.
Medicine (2024) Vol. 103, Iss. 18, pp. e38019-e38019
Open Access | Times Cited: 2
Immune cell infiltration and prognostic index in cervical cancer: insights from metabolism-related differential genes
Boyi Ma, Chenlu Ren, Yadong Yin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Boyi Ma, Chenlu Ren, Yadong Yin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review
Luc Ollivier, Camille Moreau Bachelard, Emmanuelle Renaud, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Luc Ollivier, Camille Moreau Bachelard, Emmanuelle Renaud, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
A surprising complete response to cadonilimab in a primary metastatic cervical cancer: a case report
Haijuan Yu, Jie Lin, Jian Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Haijuan Yu, Jie Lin, Jian Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy
Huiling Guo, Jianwei Wei, Yuyan Zhang, et al.
Genes & Diseases (2023) Vol. 11, Iss. 6, pp. 101158-101158
Open Access | Times Cited: 1
Huiling Guo, Jianwei Wei, Yuyan Zhang, et al.
Genes & Diseases (2023) Vol. 11, Iss. 6, pp. 101158-101158
Open Access | Times Cited: 1
Data from Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
(2024)
Open Access
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
(2024)
Open Access
Data from Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
(2024)
Open Access
Hanmei Lou, Hongbing Cai, Xin Huang, et al.
(2024)
Open Access
Place de l’immunothérapie dans la prise en charge des cancers gynécologiques
Marie Béguinot, Pierre Cornillon, Olfa Derbel, et al.
Sages-Femmes (2024) Vol. 23, Iss. 4, pp. 35-39
Closed Access
Marie Béguinot, Pierre Cornillon, Olfa Derbel, et al.
Sages-Femmes (2024) Vol. 23, Iss. 4, pp. 35-39
Closed Access
The role of Programmed Death-Ligand 1 (PDL-1) in High-Grade Cervical Intraepithelial Neoplasia (CIN2+) Development and Recurrence: A Systematic Review of Literature about HPV-CIN2+-PDL-1 Axis
Mattia Dominoni, Frediano Inzani, Andrea Gritti, et al.
Pathology - Research and Practice (2024) Vol. 264, pp. 155712-155712
Closed Access
Mattia Dominoni, Frediano Inzani, Andrea Gritti, et al.
Pathology - Research and Practice (2024) Vol. 264, pp. 155712-155712
Closed Access
The multiple facets of ovarian high grade serous carcinoma: a review on morphological, immunohistochemical and molecular features.
Angela Santoro, Giuseppe Angelico, Antonio Travaglino, et al.
Critical Reviews in Oncology/Hematology (2024), pp. 104603-104603
Closed Access
Angela Santoro, Giuseppe Angelico, Antonio Travaglino, et al.
Critical Reviews in Oncology/Hematology (2024), pp. 104603-104603
Closed Access
